Interview with Professor Kevin Outterson on the FDA’s guidance on off-label promotion and the move toward clinical trial transparency

Kevin-Outterson-260x300New England Journal of Medicine
Kevin Outterson, School of Law

Listen to audio of expert Kevin Outterson